Wednesday, November 18, 2026 Vol. I · No. 6
Business · Via CNBC

Hims & Hers launches new peptide treatments — while admitting there's more to learn about efficacy

The telehealth company will now offer compounded forms of sermorelin, glutathione, NAD+, vitamin B-12 and L-carnitine, none of which are approved by the FDA.

This is a brief. The reporting belongs to CNBC — read the complete story, with full context and credits, at the source.

Read the full story at CNBC ↗

cnbc.com

More from the Business desk